

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>HAMILTON CHRISTINE E</u> (Last) (First) (Middle) <u>2100 E 54TH STREET NORTH</u> (Street) <u>SIOUX FALLS SD 57104</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>SAB Biotherapeutics, Inc. [SABS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>12/07/2022</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/07/2022 ⁽¹⁾		A		82,987	A	\$1.205 ⁽¹⁾	3,111,334 ⁽²⁾	I	By spouse
Common Stock								4,993,090 ⁽³⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Warrant (Common Stock)	\$1.08	12/07/2022		A		82,987		06/07/2023	12/07/2027	Common Stock	82,987	(1)	82,987	I	By spouse

Explanation of Responses:

- On December 6, 2022, the Registrant entered into a securities purchase agreement with Ms. Christine Hamilton and Dr. Edward Hamilton in connection with a private placement conducted by the Registrant, pursuant to which Ms. Hamilton and Dr. Hamilton purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value \$0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of \$1.08, at a combined purchase price of \$1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.
- Reflects dispositions of 2,000,000 shares of common stock by Ms. Hamilton's spouse for bona fide estate planning purposes exempt from the report requirements of Section 16 under the Securities Exchange Act of 1934, as amended.
- Does not include: (i) 25,000 shares of common stock held by Christensen Investments, LLC, (ii) 2,909,022 shares of common stock held by the reporting persons spouse, Dr. Edward Hamilton, and (iii) 91,261 shares of common stock which the reporting person co-owns with Dr. Hamilton, all of which the reporting person may be deemed to beneficially own. The reporting person disclaims any beneficial ownership of these shares of common stock other than to the extent of any pecuniary interests the reporting person may have therein.

Remarks:

The Reporting Person states that the filing of this Form 4 shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities other than those directly owned by the Reporting Person for the purpose of Section 16, or for any other purpose.

/s/ Christine Hamilton 12/09/2022
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.